Programme

Day 1
27 Jan 2020
Day 2
28 Jan 2020

Opening

Professor Mitch Dowsett & Baroness Delyth Morgan

Baroness Delyth Morgan
Baroness Delyth Morgan
Professor Mitch Dowsett
Professor Mitch Dowsett

Highlights of the last year

BASIC
Ingunn Holen
TRANSLATIONAL
Nick Turner
PRIMARY DISEASE
Andrew Wardley
ADVANCED DISEASE
David Miles

CHAIRS: Julia Gee and Andrew Tutt

Professor Andrew Wardley
Professor Ingunn Holen
Professor Ingunn Holen

Keynote Lecture: Philip Poortmans

PERSONALISED BREAST RADIATION THERAPY – ARE WE THERE YET?

CHAIR: Charlotte Coles

Dr Philip Poortmans

Demystifying partial breast irradiation

WHY AND HOW TO DO IT?
Anna Kirby
DOES IT WORK AND WHO SHOULD HAVE IT?
Charlotte Coles
IS LESS REALLY LESS?
Philip Poortmans

CHAIRS: Charlotte Coles & Philip Poortmans

Dr Philip Poortmans
Dr Anna Kirby
Dr. Charlotte Coles
Dr Charlotte Coles

Big data in breast cancer

INTRODUCTION: THE CURRENT UK LANDSCAPE
David Dodwell
DCIS IN THE UK: THE OXFORD NINBE AND SLOANE PROJECTS
Gurdeep Mannu
TWENTY FIVE YEAR RISKS OF BREAST CANCER MORTALITY IN 500,000 WOMEN
Carolyn Taylor
ENDOCRINE THERAPY IN THE PRIMARY CARE PRESCRIPTION DATASET
Kieran Horgan

CHAIR: David Dodwell

Dr Carolyn Taylor
Professor David Dodwell
Professor David Dodwell

Why can’t we kill ER+ breast cancer?

RESISTANCE MECHANISMS TO ENDOCRINE THERAPY
Andy Sims
RESISTANCE MECHANISMS TO CDK4/6 INHIBITION
Ben O’Leary
NEW PROSPECTS FOR KILLING ER+ BREAST CANCER CELLS
Matthew Ellis

CHAIR: Jason Carroll & Stephen Johnston

Dr Matthew Ellis
Dr Andy Sims
Dr Ben O’Leary

Managing the side-effects of endocrine therapy

MANAGING THE SEXUAL IMPACT OF ENDOCRINE THERAPY
Isabel White
HOT FLUSHES
Debbie Fenlon
IMPACT ON TREATMENT ADHERENCE
Mike Dixon

CHAIR: Adrienne Morgan & Anne Armstrong

Dr Isabel White
Professor Mike Dixon
Professor Deborah Fenlon
Professor Deborah Fenlon

Keynote Lecture: Matthew Ellis

TREATMENT DEPENDENT BREAST TUMOUR EVOLUTION

Dr Matthew Ellis

DCIS – Risk estimates and management

MOLECULAR FEATURES OF DCIS AND INVASIVE BREAST CANCER
Elly Sawyer
ADDRESSING OVERTREATMENT OF SCREEN DETECTED DCIS; THE LORIS TRIAL
Matthew Wallis
NEERA PATEL LECTURE: BREAST CANCER-RELATED DEATHS IN DCIS: THE DUTCH EXPERIENCE
Jelle Wesseling

CHAIRS: Sarah Pinder & Lynda Wyld

Professor Jelle Wesseling
Dr Matthew G Wallis

Special issues in managing metastatic disease

PATIENT SPECIFIC TREATMENT SEQUENCING IN ER+ ADVANCED BREAST CANCER
Stephen Johnston
WHOLE BODY MRI IN THE MANAGEMENT OF BONE METASTASES
Anwar Padhani
IS TREATMENT OF OLIGOMETASTASES CURATIVE?
Andreas Makris

CHAIRS: Sarah Vinnicombe & Ian Smith

Dr. Andreas Makris
Dr Andreas Makris

Phenotypic and genotypic heterogeneity

GENOMICS OF INVASIVE LOBULAR BREAST CANCER
Christine Desmedt
GENOMIC LANDSCAPE OF BREAST CANCER METASTASIS AND RELAPSE
Adrian Lee
MOLECULAR EVOLUTION OF LYMPH-NODE SPREAD IN EARLY BREAST CANCER – A SURGEON’S INTEREST
Peter Barry

CHAIRS: Adrian Lee & Julia Gee

Professor Christine Desmedt

Managing the axilla

CAN WE COMPLETELEY AVOID AXILLARY SURGERY FOR SOME BREAST CANCER PATIENTS?
Monica Morrow
UK GUIDELINES FOR MANAGEMENT OF THE AXILLA POST-NAT
Julie Doughty
MODERN ROLE OF THE RADIOLOGIST IN MANAGING THE AXILLA
Anthony Maxwell

CHAIRS: Andreas Makris & Mark Sibbering

Dr Monica Morrow
Dr. Tony Maxwell
Dr Anthony Maxwell
Miss Julie Doughty

Late recurrence in ER+ disease

LATE-RECURRING ER-POSITIVE GENOMIC SUBGROUPS
Carlos Caldas
PREDICTING LATE RECURRENCE: PATIENT, TISSUE AND CIRCULATING FACTORS
Nick Turner
PREVENTING LATE RECURRENCE
Ian Smith

CHAIRS: Adrian Lee & Mark Harries

Professor Ian Smith
Professor Ian Smith

Improving breast cancer outcomes by modifying lifestyle

OBESITY AND BREAST CANCER RISK
Annie Anderson
DIET BEFORE AND AFTER A DIAGNOSIS OF BREAST CANCER OUTCOME
Michelle Harvie
EFFECTS OF EXERCISE/PHYSICAL ACTIVITY ON OUTCOMES AFTER A BREAST CANCER DIAGNOSIS
Anna Campbell

CHAIRS: Mairead Mackenzie & Liz O’Riordan

Professor Anna Campbell
Dr Michelle Harvie

Novel clinical trial design

BREAST CANCER TRIALS: CREATING DESIGNS FIT FOR CONTEMPORARY QUESTIONS
Judith Bliss
CAN BAYESIAN ADAPTIVE TRIALS BE USEFUL IN BREAST CANCER?
James Wason
PRESURGICAL WINDOW STUDIES OF NOVEL DRUGS – WHAT’S THE END-POINT?
Adrian Harris

CHAIRS: Judith Bliss & Alistair Ring

Professor James Wason
Judith Bliss
Professor Judith Bliss

Keynote Lecture: Eric Winer

CRIDLAN LECTURE
DE-ESCALATION OF MEDICAL ADJUVANT THERAPY

CHAIR: Gill Ross

18:15-19:15

Drinks reception and poster viewing

Keynote Lecture: Martine Piccart

SUCCESSES, DISAPPOINTMENTS AND THE FUTURE FOR CLINICAL TRIALS IN PRIMARY BREAST CANCER

CHAIR: Judith Bliss

The New MDMT

TOOL KITS

PANEL DISCUSSION WITH:
Charlotte Coles
Katy Hogben
Sue Holcombe
Sarah Pinder
Nicola Roche
Sarah Vinnicombe
Andrew Wardley

CHAIRS: Mark Sibbering and Debbie Fenlon

Professor Andrew Wardley
Dr. Charlotte Coles
Dr Charlotte Coles
Professor Sarah Pinder
Professor Sarah Pinder
Dr. Sarah Vinniecombe
Dr Sarah Vinnicombe

Immune therapy

TREATMENT RESPONSE AND TOXICITIES IN BREAST CANCER
Mark Harries

DIAGNOSTIC AND PROGNOSTIC ASPECTS
Roberto Salgado

CHARACTERISING IMMUNE RESPONSE
Raza Ali

CHAIRS: Andrew Tutt & Adrienne Morgan

Modelling breast cancer – moving closer to the clinic

HORMONES AND BREAST CANCER – WHY MODELS MATTER
Cathrin Brisken

A NEW 3D MODEL FOR BREAST CANCER – ALTERNATIVES TO XENOGRAFTS AND PDX
Gillian Farnie

THE CHALLENGES OF MEASURING THE RESPONSE TO IMMUNOTHERAPIES IN VIVO
Jonas Nillson

CHAIRS: Ingunn Holen & Rob Clarke

Trials in progress

DE-ESCALATION TRIALS
Judith Bliss and Dan Rea

MOLECULARLY DRIVEN TRIALS

CHAIRS: Dan Rea & Carlo Palmieri

Judith Bliss
Professor Judith Bliss

Keynote Lecture: Judy Garber

GENETICS AND BREAST CANCER RISK

CHAIR: Trevor Powles

Breast Cancer Risk and Prevention

RECENT LESSIONS FROM THE WHI STUDY
Rowan Chlebowski

CHEMOPREVENTION OF BREAST CANCER – WHERE HAVE WE GO TO?
Jack Cuzick

LOW-DOSE TAMOXIFEN FOR BREAST CANCER PREVENTION
Andrea Decensi

CHAIRS: Trevor Powles & Anne Armstrong

Prognostic and Predictive Profiling

PREDICT VS NPI
Paul Pharoah

CAN MRNA REPLACE IHC FOR ER?
Adrian Lee

KI67 – WILL IT EVER MAKE IT? A REPORT OF 10 YEARS’ WORK FROM THE INTERNATIONAL KI67 IN BREAST CANCER WORKING GROUP
Mitch Dowsett

CHAIRS: Kieren Horgan & Steffi Oesterreich

Professor Mitch Dowsett
Professor Mitch Dowsett

Special issues for elderly patients

GENERAL PRESENTATION
KL Cheung

BRIDGING THE AGE GAP
Lynda Wyld

DEMENTIA AND DECISION MAKING
Yasmin Jauhari

CHAIRS: KL Cheung & Alistair Ring

Professor Kwok-Leung Cheung
Professor Lynda Wyld

Keynote Lecture: Monica Morrow

DE-ESCALATING SURGERY FOR BREAST CANCER

CHAIR: Julie Doughty

Dr Monica Morrow

Minimising mastectomy

NEOADJUVANT CHEMOTHERAPY
Sibylle Loibl

BREAST CONSERVING SURGERY FOR MULTIFOCAL TUMOURS
Mike Dixon

ONCOPLASTIC SURGERY
Katy Hogben

CHAIRS: Julie Doughty & Andreas Makris

Professor Mike Dixon

Special issues in managing young patients

CHOOSING ENDOCRINE TREATMENT
Dan Rea

MANAGING FERTILITY IN BREAST CANCER
Melanie Davies

PREGNANCY AFTER BREAST CANCER
Sibylle Loibl

CHAIRS: Andrew Wardley & Liz O’Riordan

Translating new therapeutic opportunities

TARGETING CDK7 IN ER+ BREAST CANCER
Simak Ali

ANDROGEN RECEPTOR AGONISTS FOR AR+ DISEASE
Carlo Palmieri

RATIONALE AND PROGRESS IN TARGETING FOXA1
Jason Carroll

CHAIRS: Rob Clarke & Adrian Harris

Professor Jason Carroll

Young Clinical Leaders

TRAINEE COLLABORATIVE RESEARCH – A SUCCESSFUL NEW STORY
Cliona Kirwan

THE ACHIEVEMENTS OF THE MAMMARY FOLD COLLABORATIVE AND CURRENT PROJECTS
Lisa Sheehan

MULTIDISCIPLINARY COLLABORATION – INTRODUCTION TO THE BCTRCG
Ellen Copson

DRAGON’S DEN

ACADEMIC CAREER PATHWAYS
Cliona Kirwan

WHY AND HOW TO JOIN A TRIAL MANAGEMENT GROUP
Indrani Bhattacharya

Professor Cliona Kirwan
Dr Ellen Copson
Dr Lisa Sheehan